Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EyePoint Pharmaceuticals, Inc.
A study to evaluate Efficacy and Safety of two doses of EYP-1901 in subjects with DME
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of diabetes mellitus in the study eye, with disease onset any time prior to the Screening Visit
Previously treated with at least 1 intravitreal anti-VEGF in the last 6 months in the study eye at least 8 weeks prior to the Screening Visit.
BCVA letter score of 35 letters (20/200 Snellen equivalent) to 75 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).
You may not be if
Any current or history of ocular disease other than DME
BCVA using ETDRS charts \<30 letters (20/250 Snellen equivalent) in the fellow eye.
Active ocular inflammation or active infection in either eye at Baseline (Day 1).
Clareo Health | Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
